NASAL & PULMONARY DRUG
DELEVARY SYSTEM & ITS
APPLICATION
BY
DEBAJYOTI BHATTACHARYA
Under guidance of Prof. Sateesha. S.B
Introduction:
 It is also a type of muco-adhesive drug delivery system.
 Drugs are administered through nasal cavity by ...
 The nasal mucosa has been considered as a
potential administration route to achieve faster and
higher level of drug abso...
 Pathologic conditions such as cold or allergies may alter
significantly the nasal bioavailability.
 Low bio-availabilit...
ANATOMY & PHYSIOLOGY OF NOSE
 The nose is an important part of the face; it gives the individual his
characteristic appea...
 The cartilaginous part is made up of 2 pairs of lateral
cartilages (upper lateral cartilages and lower lateral cartilage...
2.The internal nose (the nasal cavity )
 The nasal cavity is divided by midline partition (the nasal
septum) into right a...
 Each cavity has a roof ,floor, medial and lateral walls .The
floor is formed by the palatine process of the maxilla and ...
 The lateral wall is the most complex, it contains 3 shelf –like
projections into the nasal cavity called the turbinates ...
 The inferior meatus contain the opening of
nasolacrimal duct.
 The middle meatus contains the ostia (openings) of the
f...
 While the external carotid artery supplies the nose through it`s
maxillary branch and small contribution of the facial a...
NERVE SUPPLY OF THE NASAL CAVITY
 1- Olfactory nerves: they arise from a specialized
olfactory epithelium in the olfactor...
THE PHYSIOLOGY OF THE NOSE
 The nose has several functions
 1- Respiratory function
 a- It provides an airway for respi...
 3- Investigations:
 A- Radiology
 1-plain radiography
 the nasal bones usually demostated by plain lateral radiograph...
MECHANISM OF DRUG ABSORPTION
 The first step in the absorption of drug from the nasal cavity is passage
through the mucus...
Following mechanisms have been proposed :
I. The first mechanism involves an aqueous route of transport which is
also know...
FACTORS INFLUENCING NASAL DRUG
ABSORPTION
 Factors Related to Drug
 a) Lipophilicity
 On increasing lipophilicity, the ...
c)Polymorphism
 Polymorphism is known to affect the dissolution rate and
solubility of drugs and as well as their absorpt...
 e) Partition Coefficient and pKa
 As per the pH partition theory, unionized species are absorbed
better compared with i...
 f) Solubility & Dissolution Rate
 Drug solubility and dissolution rates are important factors
in determining nasal abso...
B) Factors Related to Formulation
1) Physicochemical Properties of the Formulation
a) pH and Mucosal Irritancy
 The pH of...
POLYMERS FOR NASAL DDS:
DOSAGE FORM USED FOR DEVELOPING THE
FORMULATION
 1.Nasal drop
 2.Nasal spray
 3.Nasal gel
 4.Nasal powder
 1.Nasal dr...
2.NASAL SPRAYS
 Both solution and suspension formulations can be formulated
into nasal sprays.
 Due to the availability ...
3.NASAL GELS
 Nasal gels are high-viscosity thickened solutions or
suspensions.
 Until the recent development of precise...
4.NASAL POWDERS
 This dosage form may be developed if solution and suspension
dosage forms cannot be developed e.g.,due t...
EVALUATION OF NASAL FORMULATIONS:-
In vitro diffusion studies:
 The nasal diffusion cell is fabricated in glass.
 The wa...
CONTINUED
 The donor tube is placed such a way that it just touches
the diffusion medium in recipient chamber at
predeter...
(B) In vivo nasal absorption studies:-
animal models for nasal absorption studies :
these models are 2 types.
a. Whole ani...
 The passage of the naso palatine track is sealed so that the
the drug solution is not drained from nasal cavity through ...
Ex vivo nasal perfusion models:-
 Surgical preparation is same that of in vivo rat model
 During perfusion studies a fun...
APPLICATIONS
Delivery of non-peptide pharmaceuticals
Delivery of diagnostic drugs
Delivery of peptide-based pharmaceuticals
 1. Delivery of non-peptide pharmaceuticals
Drugs with extensive pre-systemic metabolism, such as
 - progesterone
 - es...
2. Delivery of peptide-based pharmaceuticals
 Peptides & proteins have a generally low oral bioavailability
because of th...
 3. Delivery of diagnostic drugs
 Diagnostic agents such as
Phenolsulfonphthalein – kidney function
Secretin – pancreati...
REFERENCES
1. CONTROLLED DRUG DELIVERY CONCEPTS
AND ADVANCES BY-S.P.VYAS & R.P.KHAR
2. MODERN PHARMACEUTICS FOURTH EDITION...
PULMONARY DRUG
DELIVERY SYSTEM
INTRODUCTION
 Pulmonary route was use to treatment of different respiratory
diseases from the last decade. The inhalation...
FIG 1: DIFFERENT REGIONS OF THE HUMAN
RESPIRATORY TRACT
ANATOMY AND PHYSIOLOGY OF
LUNGS
1) Lung regions:-
 The respiratory tract starts at the nose and terminates deep
in the lu...
3) Tracheo-bronchial region:-
 This is also referred to as the “central” or “conducting
airways”, which starts at the lar...
Pulmonary epithelium:-
 The lung contains more than 40 different cell types, of which
more than six line the airways.
 T...
The alveolar region:-
 This is devoid of mucus and has a much flatter epithelium,
which becomes the simple squamous type,...
 Ciliated cells:-
 In the trachea bronchial region, a high proportion of the
epithelial cells are ciliated such that the...
MECHANISMS OF PARTICLE DEPOSITION IN THE
AIRWAYS
 Effective resistance mechanisms may have involved may reduces
the burde...
Inertial impaction
 This is the main deposition mechanism forparticles >1 μm in the
upper tracheo-bronchialregions.
 A p...
Sedimentation:-
 By the settling under gravity the particles may deposited. It becomes highly important for
particles tha...
PHYSIOLOGICAL FACTORS AFFECTING PARTICLE
DEPOSITION IN THE AIRWAYS :
Lung morphology:-
 Each successful production of the...
ADVANTAGES :
 1) It is needle free pulmonary delivery.
 2) It requires small and fraction of oral dose.
 3) Low concent...
APPLICATIONS:
1)In Asthma and COPD:
 Asthma is a chronic lung that disease is characterized by
inflammation and narrowing...
CONTINUED
3)In cystic fibrosis
 Now a days cystic fibrosis is very common disease pulmonary
delivery played an important ...
CONTINUED
5)In Migraine:
Ergotamine is the drug of choice of migraine & earlier it has been used
through inhalation (pulmo...
RECENT TECHNOLOGIES OF
PULMONARY DRUG DELIVERY:
 Nebulizer:
 In jet nebulizers, an aerosol is prepared by a high velocit...
METERED DOSE INHALER (MDI):
CONTINUED
 These are the most common device for administration of
aerosolized drugs.
 In this technique, a medication is...
REFERENCE
1. CONTROLLED DRUG DELIVERY CONCEPTS
AND ADVANCES BY-S.P.VYAS & R.P.KHAR
2. MODERNPHARMACEUTICS FOUTH EDITION
BY...
ThAnK u
Nasal & pulmonary drug delevary system & its application
Nasal & pulmonary drug delevary system & its application
Nasal & pulmonary drug delevary system & its application
Nasal & pulmonary drug delevary system & its application
of 61

Nasal & pulmonary drug delevary system & its application

Published on: Mar 3, 2016
Published in: Health & Medicine      Business      
Source: www.slideshare.net


Transcripts - Nasal & pulmonary drug delevary system & its application

  • 1. NASAL & PULMONARY DRUG DELEVARY SYSTEM & ITS APPLICATION BY DEBAJYOTI BHATTACHARYA Under guidance of Prof. Sateesha. S.B
  • 2. Introduction:  It is also a type of muco-adhesive drug delivery system.  Drugs are administered through nasal cavity by different dosage forms like solutions , emulsions , gels etc. Nasal enzymes:  Cytochrome p-450 dependent oxygenase , lactate dehydrogenase , oxydoreductase , acid hydrolases, esterases, lactic dehydrogenases, malic enzymes, lysosomal proteinases, steroid hydroxylases etc. Nasal pH:  adult nasal secretion pH: 5.5-6.5  Infants & children : 5-6.7.  It becomes alkaline in conditions such as acute rhinitis, acute sinusitis.  Lysosome in the nasal secretion helps as antibacterial & its activity is diminished in alkaline pH.
  • 3.  The nasal mucosa has been considered as a potential administration route to achieve faster and higher level of drug absorption. This is due to the large surface area & porous endothelial membrane.  The avoidance of first-pass metabolism, and ready accessibility. Route of administration is the poor contact of the formulations with the nasal mucosa.  Researchers became interested in the nasal route for the systemic delivery of medication due to high degree of vascularization and permeability of the nasal mucosa.
  • 4.  Pathologic conditions such as cold or allergies may alter significantly the nasal bioavailability.  Low bio-availability for proteins and peptides and polar drugs.  Once administered, rapid removal of the therapeutic agent from the site of absorption is difficult.  The histological toxicity of absorption enhancers used in nasal drug delivery system is not yet clearly established.  Relatively inconvenient to patients when compare to oral drug delivery systems since there is a possibility of nasal irritation  Rapid muco ciliary clearance will occurs.  Chances of immunologic reactions Disadvantages:
  • 5. ANATOMY & PHYSIOLOGY OF NOSE  The nose is an important part of the face; it gives the individual his characteristic appearance.  The nose is divided into 2 parts:  1- The external nose.  2- The internal nose (nasal cavities) 1-The external nose:  It is the prominent part of the face, pyramidal in shape .the apex is the tip of the nose; the base is the attached area to the forehead. The external nose projecting downwards and is perforated by two apertures called the nostrils separated by the columella.  The lateral surfaces joined along the dorsum of the nose where it meets the forehead.  The external nose has a skeleton made up of bony and cartilaginous parts .  The bony part is the two nasal bones, the nasal processes of the frontal and maxillary bones .
  • 6.  The cartilaginous part is made up of 2 pairs of lateral cartilages (upper lateral cartilages and lower lateral cartilages ) these cartilages are connected by fibrous tissue. The lower lateral cartilages help in shaping the nostrils.  The outer surface is covered by skin which is thin and mobile above and thick andadherent to the subcutaneous structures near the tip.
  • 7. 2.The internal nose (the nasal cavity )  The nasal cavity is divided by midline partition (the nasal septum) into right and left chambers,. It extends from the nostrils in front into the choanae behind (where it opens into the nasopharynx)  The entrance to the nasal cavity is called the nasal vestibule which ends at themucocutaneous junction, it is lined by skin and contains skin appendages.  the vestibule is a common site of boil development because it is hair bearing area  The rest of nasal cavity lined by respiratory mucosa ( pseudo- stratified columnar ciliate epithelium ), and small area lined by olfactory epithelium.
  • 8.  Each cavity has a roof ,floor, medial and lateral walls .The floor is formed by the palatine process of the maxilla and the horizontal process of palatine bone.  The roof is narrow and is formed (from behind forward) by the body of the sphenoid,cribriform plate of the ethmoid and the frontal bone.  Clinical point(4): cribriform plate is a thin plate of bone and easily to be fractured in head injury and may associated with CSF leak through the nose.  The medial wall (the nasal septum) is an osteocartilaginous partition covered by adherent mucoperichondrium and mucoperiostium .The upper part is formed by the perpendicular plate of the ethmoid bone ,the posterior part by the vomer and theanterior portion is formed by septal cartilage.
  • 9.  The lateral wall is the most complex, it contains 3 shelf –like projections into the nasal cavity called the turbinates ( the superior, middle and the inferior turbinates )  The groove below each turbinate is referred to as a meatus.There are 3 meati calledthe superior ,middle and the inferior meatus) into these meati the paranasal sinuses open and join the nasal cavity.The area above the superior turbinate is called the sphenoethmoial recess.
  • 10.  The inferior meatus contain the opening of nasolacrimal duct.  The middle meatus contains the ostia (openings) of the frontal ,maxillary and the anterior ethmoid sinuses.  3 The superior meatus receives the opening of the posterior ethmoid sinus.  The sphenoethmoidal recees receives the opening of the sphenoid sinus.  Blood supply of the nasal cavity  It supplied by branches of internal and external carotid arteries.  i branches of the internal carotid artery that supply the nose are the anterior and posterior ethmoidal arteries
  • 11.  While the external carotid artery supplies the nose through it`s maxillary branch and small contribution of the facial artery.  The internal carotid artery and external carotid artery branches anastomose freely in the nose ,the common site of anastmosis is in the antero-inferior part of the nasal septum (little`s area) ,the arteries that share in this anastmosis are the sphenopalatine artery ,greater palatine artery, superior labial artery and branch from the anterior ethmoidal artery .  The venous drainage  The nose characterized by rich submucosal plexus of venous sinusoids ,these drained by veins that accompany the arteries.
  • 12. NERVE SUPPLY OF THE NASAL CAVITY  1- Olfactory nerves: they arise from a specialized olfactory epithelium in the olfactory  mucosa .they ascend through the cribriform plate to reach the olfactory bulb.  2- Nerves of ordinary sensation: They are from the ophthalmic and maxillary  divisions of the trigeminal nerve.  3-vasomotor nerve supply (the autonomic nerve supply):  A-Parasympathetic when it is simulated it causes vasodilatation. And stimulate  glandular secretion  B- Sympathetic nerves it causes vasoconstriction when stimulated and inhibit  glandular secretion
  • 13. THE PHYSIOLOGY OF THE NOSE  The nose has several functions  1- Respiratory function  a- It provides an airway for respiration.  b- Filtration of the inspired air.  c- Humidification of the inspired air.  d- Adjusts the temperature of he inspired air.  2- Olfactory function.  3- Phonatory function. It provides the voice with a resonant quality.  Investigations:  Approach to patient with nasal disease start from  1-Adequate history  2-Examination of the nose by anterior rhinoscopy using nasal speculum and  posterior rhinoscopy by post nasal mirror,and by edoscopic examination which can be  6  done under local anaesthesia by using either fibro-optic endoscope(flexible)or rigid  endoscope
  • 14.  3- Investigations:  A- Radiology  1-plain radiography  the nasal bones usually demostated by plain lateral radiograph.  Radiography of the paranasal sinuses; there are several standard views of the sinuses  1-Occipitomental mental view it the most commonly requested view to demonstrate  the maxillary ,frontal and sphenoid sinuses  2-other views are occipittofrontal view, the lateral view and submentovertical view  2-Computerizd axial tomography (ct scan )  Advantages it delineates fine bony outline and soft tissue and is the preferred imaging  technique for detailed anatomy especially in relation to the skull base and the orbit  Disadvantage Is the ionizing radiation .  3-Magnaic resonanane imaging (MRI)  It delineate soft tissue better than ct scan and can distinguish between retained  secretion and soft tissue .It is an important investigation where the disease extends  outside the nose and sinuses for example into the anterior cranial fossa .
  • 15. MECHANISM OF DRUG ABSORPTION  The first step in the absorption of drug from the nasal cavity is passage through the mucus . Small, unchanged particles easily pass through this layer. However, large or charged particles may find it more difficult to cross.  Mucin, the principle protein in the mucus, has the potential to bind to solutes, hindering diffusion.  Structural changes in the mucus layer are possible as a result of environmental changes (i.e. pH, température, etc.)subsequent to a drug’s passage through the mucus.  There are several mechanisms for absorption through the mucosa.These include transcellular or simple diffusion across the membrane, paracellular transport via movement between cell and transcytosis by vesicle carriers .  Drug absorption are potential metabolism before reaching the systemic circulation and limited residence time in the cavity.
  • 16. Following mechanisms have been proposed : I. The first mechanism involves an aqueous route of transport which is also known as the paracellular route. This route is slow and passive. There is an inverse log-log correlation between intranasal absorption and the molecular weight of water-soluble compounds. Poor bioavailability was observed for drugs with a molecular weight greater than 1000 Daltons . II. The second mechanism involves transport through a lipoidal route that is also known as the transcellular process and is responsible for the transport of lipophilic drugs that show a rate dependency on their lipophilicity. Drugs also cross cell membranes by an active transport route via carrier-mediated means or transport through the openingof tight junctions.
  • 17. FACTORS INFLUENCING NASAL DRUG ABSORPTION  Factors Related to Drug  a) Lipophilicity  On increasing lipophilicity, the permeation of the compound normally increases through nasal mucosa because of high lipophilicity though it has some hydrophilic character.eg: alprenolol and propranolol.  b) Chemical Form  Its an important factor for absorption.  Conversion of the drug into a salt or ester form can alter its absorption. eg: In-situ nasal absorption of carboxylic acid esters of L-Tyrosine was significantly greater than that of L-Tyrosine.
  • 18. c)Polymorphism  Polymorphism is known to affect the dissolution rate and solubility of drugs and as well as their absorption through biological membranes.  It is therefore advisable to study the polymorphic stability and purity of drugs for nasal powders or suspensions . d) Molecular Weight  In the case of lipophilic compounds, a direct relationship exists between the Molecular Weight and drug permeation where as water soluble compounds depict an inverse relationship.  The permeation of drugs less than 300Da is not significantly influenced by the physicochemical properties of the drug, which will mostly permeate through aqueous channels of the membrane. By contrast, the rate of permeation is highly sensitive to molecular size for compounds with MW = >300 Da.
  • 19.  e) Partition Coefficient and pKa  As per the pH partition theory, unionized species are absorbed better compared with ionized species and the same holds true in the case of nasal absorption.  Quantitative relationship between the physicochemical properties of drugs and their nasal absorption, the results showed that a quantitative relationship existed between the partition coefficient and the nasal absorption constant .  The nasal absorption of weak electrolytes such as salicylic acid and amino-pyrine was found to be highly dependent on their degree of ionization.  Although for amino-pyrine, the absorption rate increased with the increase in pH and was found to fit well to the theoretical profile.  Substantial deviations were observed with salicylic acid. The authors concluded that perhaps a different transport pathway, along with the lipoidal pathway, eg:salicylic Acid pathways.
  • 20.  f) Solubility & Dissolution Rate  Drug solubility and dissolution rates are important factors in determining nasal absorption from powders and suspensions.  The particles deposited in the nasal cavity need to be dissolved prior to absorption. If a drug remains as particles or is cleared, no absorption takes place.
  • 21. B) Factors Related to Formulation 1) Physicochemical Properties of the Formulation a) pH and Mucosal Irritancy  The pH of the formulation, as well as that of nasal surface, can affect a drug’s permeation. To avoid nasal irritation, the pH of the nasal formulation should be adjusted to 4.5–6.5 . In addition to avoiding irritation, it results in obtaining efficient drug permeation and prevents the growth of bacteria. b) Osmolarity  Because of the effect of osmolarity on the absorption isotonic solutions are usually preferred for administration for shrinkage of the nasal epithelial mucosa.  This results in increased permeation of the compound resulting from structural changes  c) Viscosity  A higher viscosity of the formulation increases contact time between the drug and the nasal mucosa there by increasing the time for permeation.  At the same time, highly viscous formulations interfere with the normal functions like ciliary beating or mucociliary clearance and thus alter the permeability of drugs.
  • 22. POLYMERS FOR NASAL DDS:
  • 23. DOSAGE FORM USED FOR DEVELOPING THE FORMULATION  1.Nasal drop  2.Nasal spray  3.Nasal gel  4.Nasal powder  1.Nasal drop  Most simple and convenient systems developed for nasal delivery.  The main disadvantage of this system is the lack of dose precision and therefore nasal drops may not be suitable for prescription products .  It has been reported that nasal drops deposit human serum albumin in the nostrils more efficiently than nasal sprays
  • 24. 2.NASAL SPRAYS  Both solution and suspension formulations can be formulated into nasal sprays.  Due to the availability of metered dose pumps and actuators, a nasal spray can deliver an exact dose from 25 to 200 L.  The particle size and morphology(for suspensions) of the drug and viscosity of the formulation determine the choice of pump and actuator assembly.  Solution and suspension sprays are preferred over powder sprays because powder results in mucosal irritation .
  • 25. 3.NASAL GELS  Nasal gels are high-viscosity thickened solutions or suspensions.  Until the recent development of precise dosing devices, there was not much interest in this system.  The advantages of a nasal gel include the reduction of post- nasal drip due to high viscosity, reduction of taste impact due to reduced swallowing, reduction of anterior leakage of the formulation, reduction of irritation by using soothing/emollient  Excipients and target delivery to mucosa for better absorption
  • 26. 4.NASAL POWDERS  This dosage form may be developed if solution and suspension dosage forms cannot be developed e.g.,due to lack of drug stability.  The advantages to the nasal powder dosage forms are the absence of preservative and superior stability of the formulation. However, the suitability of the powder formulation is dependent on the solubility, particle size, aerodynamic properties and nasal irritancy of the active drug and/or excipients.  Local application of drug is another advantageof this system but nasal mucosa irritancy and metered dose delivery are some of the challenges for formulation  Generally, the absorption enhancers act via one of the following mechanisms:  • Inhibit enzyme activity;  • Reduce mucus viscosity or elasticity;  • Decrease muco-ciliary clearance;  • Open tight junctions;  • Solubilize or stabilize the drug.  Absorption enhancers are generally classified as physical and chemical enhancers. Chemical enhancers act by destroying
  • 27. EVALUATION OF NASAL FORMULATIONS:- In vitro diffusion studies:  The nasal diffusion cell is fabricated in glass.  The water jacketed recipient chamber has total capacity of 60 ml & a flanged top of about 3mm. the lid has 3 openings, each for sampling, thermometer, and a donor tube has internal diameter of 1.13 cm.  The nasal mucosa of sheep was separated from sub layer bony tissues & stoned in distilled water containing few drops at gentamycin injection. After the complete removal of blood from mucosal surface ,is attached to donor chamber tube.
  • 28. CONTINUED  The donor tube is placed such a way that it just touches the diffusion medium in recipient chamber at predetermined intervals, samples(0.5ml) from recipient withdraw & transferred to amber colored ampoules .  The samples withdrawn is suitably replaced.  The samples are estimated for drug content by suitable analytical technique, throughout the experiment temp is maintained at 37˚c.
  • 29. (B) In vivo nasal absorption studies:- animal models for nasal absorption studies : these models are 2 types. a. Whole animal or in vivo model. b. Isolated organ perfusion or ex vivo model. (a) in vivo model: 1)e.g. Rat model:-  The rat is anesthetized by intra-peritoneal injection of sodium pentobarbital. An incision is made in the neck & trachea is cannulated with a polyethylene tube.  Another tube is inserted for through the oesophagus towards the posterior region of the nasal cavity.
  • 30.  The passage of the naso palatine track is sealed so that the the drug solution is not drained from nasal cavity through the mouth.  The drug solution is delivered to the nasal cavity through the nostril or through the cannulating tubing.  The blood samples are collected from the only femoral vein. As all the probable outlets are blocked, the drug can be only absorbed and transported into the systemic circulation by penetration or diffusion. 2) e.g.: rabbit model. 3)e.g.: dog model. 4)e.g.: monkey model.
  • 31. Ex vivo nasal perfusion models:-  Surgical preparation is same that of in vivo rat model  During perfusion studies a funnel is placed between the nose & reservoir to minimize the loss of drug solution.  The drug solution is placed in reservoir maintained at 37c & is circulated through the nasal cavity of the rat with a peristaltic pump the perfusion solution passes out from nostrils &runs again into the reservoir, stirred continuously.  Amount of drug is absorbed is estimated by measuring the residual drug concentration in the per fusing solution. the drug activity due to stability problem may lost during the experiment.  This is especially for peptides & protein drugs that may undergo proteolysis & aggregation.
  • 32. APPLICATIONS Delivery of non-peptide pharmaceuticals Delivery of diagnostic drugs Delivery of peptide-based pharmaceuticals
  • 33.  1. Delivery of non-peptide pharmaceuticals Drugs with extensive pre-systemic metabolism, such as  - progesterone  - estradiol  - propranolol  - nitroglycerin  - sodium chromoglyate can be rapidly absorbed through the nasal mucosa with a systemic bioavailability of approximately 100%
  • 34. 2. Delivery of peptide-based pharmaceuticals  Peptides & proteins have a generally low oral bioavailability because of their physico-chemical instability and susceptibility to hepato-gastrointestinal first-pass elimination. Eg. Insulin, Calcitonin, Pituitary hormones etc.  Nasal route is proving to be the best route for such biotechnological products.
  • 35.  3. Delivery of diagnostic drugs  Diagnostic agents such as Phenolsulfonphthalein – kidney function Secretin – pancreatic disorders Pentagastrin – secretory function of gastric acid are administered through the nasal route.
  • 36. REFERENCES 1. CONTROLLED DRUG DELIVERY CONCEPTS AND ADVANCES BY-S.P.VYAS & R.P.KHAR 2. MODERN PHARMACEUTICS FOURTH EDITION BY- BANKER & RHODES 3. ADVANCE IN CONTROLLED AND NOVEL DRUG DELIVERY BY-N.K. JAIN 4. WWW.Google.com
  • 37. PULMONARY DRUG DELIVERY SYSTEM
  • 38. INTRODUCTION  Pulmonary route was use to treatment of different respiratory diseases from the last decade. The inhalation therapies involved the use of leaves from plants, vapors from aromatic plants like balsams, and myhrr.  In the 1920 s adrenaline can introduce as a nebulizer solution, in 1925 nebulizer porcine insulin was use in investigational studies in diabetes, and in 1945 pulmonary delivery of the newly revealed penicillin was investigated.  steroids had been introduced in between 1950s for the treatment of asthma and nebulizers were enjoy widely use. In 1956 the pressured metered dose inhaler (pMDI) was placed.  lung associated bigger protein molecules may degrade into the gastrointestinal situation and are excreted through the first pass metabolism into the liver which can be transferred through the pulmonary route if deposited in the respiratory passage of the lungs .
  • 39. FIG 1: DIFFERENT REGIONS OF THE HUMAN RESPIRATORY TRACT
  • 40. ANATOMY AND PHYSIOLOGY OF LUNGS 1) Lung regions:-  The respiratory tract starts at the nose and terminates deep in the lung at an alveolar sac. There are a number of schemes for categorizing the various regions of the respiratory tract. 2) Nasopharyngeal region:-  This is also referred to as the “upper airways”, which involves the respiratory airways from the nose down to the larynx.
  • 41. 3) Tracheo-bronchial region:-  This is also referred to as the “central” or “conducting airways”, which starts at the larynx and extends via the trachea, bronchi, and bronchioles and ends at the terminal bronchioles. 4) Alveolar region:-  This is also referred to as the “respiratory airways”, “peripheral airways” or “pulmonary region”,Comprising the respiratory bronchioles, alveolar ducts and alveoli.  The term “pulmonary” can be used to the alveolar region. The use of “upper respiratory tract” (i.e. NP plus trachea) and “lower respiratory tract”is also common place.
  • 42. Pulmonary epithelium:-  The lung contains more than 40 different cell types, of which more than six line the airways.  The diversity of pulmonary epithelia can be illustrated by examining its structure at three principal levels. The bronchi:-  These are lined predominantly with ciliated and goblet cells. Some serous cells, brush cells and Clara cells are also present with few Kulchitsky cells. The bronchioles:-  These are primarily lined with ciliated cuboidal cells. The frequency of goblet and serous cells decreases with progression along the airways while thenumber of Clara cells increases.
  • 43. The alveolar region:-  This is devoid of mucus and has a much flatter epithelium, which becomes the simple squamous type,0.1–0.5 μm thick.  Two principal epithelial cell types are present: Type-I pneumocytes: Thin cells offering a very short airways- blood path length for the diffusion of gasesand drug molecules. Type-I pneumocytes occupy about 93% of the surface area of the alveolar sacs. • Type-II pneumocytes: Cuboidal cells that store and secrete pulmonary surfactant. Alveolar macrophages account for ~ 3% of cells in the alveolar region.  These phagocytic cells scavenge and transport particulate matter to the lymph nodes and the mucociliary escalator.
  • 44.  Ciliated cells:-  In the trachea bronchial region, a high proportion of the epithelial cells are ciliated such that there is a near complete covering of the central airways by cilia.  Towards the periphery of the tracheobronchial region,the cilia are less abundant and are absent in the alveolar region. The ciliated cells each have about 200 cilia with numerous interspersed microvilli, of about 1–2 μm in length. The cilia are hair-like projections about 0.25 μm in diameter and 5 μm in length.  They are submersed in an epithelial lining fluid, secreted mainly from the serous cells in the sub-mucosal glands.  The tips of the cilia project through the epithelial lining fluid into a layer of mucus secreted from goblet cells.  The cilia beat in an planned fashion to propel mucus along the airways to the throat.
  • 45. MECHANISMS OF PARTICLE DEPOSITION IN THE AIRWAYS  Effective resistance mechanisms may have involved may reduces the burden of external particles enter the airways, and clearing those it may achieve something in being stored.  Therapeutic aerosols are two-phase colloidal systems in that the drug is contained in a dispersed phase they may have a solid,  liquid or combination of the two, based on themethod and formulation of aerosol generation.  Evidently for effective therapy, the drug must have obtain able to the lung in aerosol droplets or particles that deposit in the specific lung region and insufficient quantity to be effective.  The respiratory resistance mechanisms of mucociliary clearance and phagocytosis by macrophages may act upon insoluble particles.  Aerosol particle dissolution they may slow and the drug may then subsequently to be subject to enzymatic deprivation before it reaches to its specific site of pharmacological action. Aerosols for pulmonary drug delivery are transported from the mouth.
  • 46. Inertial impaction  This is the main deposition mechanism forparticles >1 μm in the upper tracheo-bronchialregions.  A particle having a large momentum it may not able to follow the altering direction of the inspired air as it transferred the bifurcations and it will show result to collide with the airway walls as it continues on its original course. Description of particle deposition mechanisms at an airway branching site  Impaction it mainly occurs near the bifurcations, certainly the impaction of particles from tobacco smoke on the bifurcations may be one cause whythese sites are often the foci for lung tumors.  The prospect of inertial impaction will be dependents upon particle momentum, thus particles with higher densities or larger diameter and those travelling in airstreams of higher velocity will show superior impaction.
  • 47. Sedimentation:-  By the settling under gravity the particles may deposited. It becomes highly important for particles that reach airways where the airstream velocity is relatively low, e.g. the bronchioles and alveolar region.  The fraction of particles depositing by this mechanism it may dependent upon the time the particles use in these regions. Brownian diffusion:-  This is of minor significance for particles >1 μm.  Particles smaller than this size are displaced by a sequentially bombardment of gas molecules, which may results in particle collision with the airway walls. The chances of particle deposition by diffusion increases with the particle size decreases.  Brownian diffusion is also more common in regions where airflow is very low or absent, e.g. in the alveoli.  Deposition: ie interception, is of important for fibers but it may not for drug delivery.Generally Particles bigger than 10 μm will have impact in the upper airways and are rapidly removed by swallowing, coughing and mucociliary processes.  The particles in the size range 0.5–5 μm may break away from impaction in the upper airways and may  deposit by sedimentation and impaction in the lowerTB and A regions.  If the aerosol particle size is between the 3 and 5 μm then deposition it mainly occur in the TB region. If the particles are smaller than the 3 μm then appreciable deposition in the A region is likely to occur.
  • 48. PHYSIOLOGICAL FACTORS AFFECTING PARTICLE DEPOSITION IN THE AIRWAYS : Lung morphology:-  Each successful production of the tracheobronchial tree produces airways of falling diameter and length.  Every bifurcation results in an increase possibility for impaction and the decrease in airway diameter is associated with a smaller displacement necessary a particle to make contact with a surface. Inspiratory flow rate:-  When the inspiratory flow rate increases they enhance deposition by impaction in the first few generations of the TB region. The increase in flow not only increase particle momentum but also result in an increase in turbulence, mostly in the larynx and trachea, which itself will enhance impaction in theproximal tracheo-bronchial region.
  • 49. ADVANTAGES :  1) It is needle free pulmonary delivery.  2) It requires small and fraction of oral dose.  3) Low concentration in the systemic circulation are  associated with reduced systemic side effects.  4) Rapid Onset of action  5) Avoidance of gastrointestinal upset  6) Degradation of drug by liver is avoided in  pulmonary drug delivery .  DISADVANTAGES  1) Oropharyngeal deposition gives local side effect.  2) Patient may have difficulty using the pulmonary drug devices correctly
  • 50. APPLICATIONS: 1)In Asthma and COPD:  Asthma is a chronic lung that disease is characterized by inflammation and narrowing of airways & it causes recurring period so wheezing, shortness of breath, chest tightness and coughing. For treatment of asthma for ex-levosalbutamo linhalers which showgreater efficacy as compare tosalbutamol.  COPD means chronic obstructive pulmonary diseases. For the treatment of COPD titropium inhalers are present in market.  2) pulmonary delivery inpatients on ventilators:  Now a days Baby mask is used aspatient device &. is attached to spacer for small tidal volumes and low inspiratory flow rates infant and young Childers.  We can easily give medication to child up to 2 years by using baby mask .
  • 51. CONTINUED 3)In cystic fibrosis  Now a days cystic fibrosis is very common disease pulmonary delivery played an important role in the treatment of CF for decades. The main aim of aerosol system is to deliver drugs to infants and children’s. Ex:N-Acetylcysteine, Tobramycin-spray dried. 4)In Diabetes  Diabetes is deficiency of insulin secretion or resistance. Insulin inhalers would work much like asthma inhalers.  The products fall into two main groups the dry powder formulations and solution, which are delivered through different patented inhaler systems. E.g. Novel pMDI formulations for pulmonary delivery of proteins
  • 52. CONTINUED 5)In Migraine: Ergotamine is the drug of choice of migraine & earlier it has been used through inhalation (pulmonary route). 6)In Angina Pectoris: Nitroglycerine is drug of choice for angina pectoris has been given generally by sublingual route . Isosorbide aerosol has also been reported useful in hypertensive crisis. In United States inhalation therapy for angina-pectoris is very well accepted . 7) Role in vaccination :  Nearly 100 vaccines are approved in the U. S. About half of these prevent respiratory infections, yet all are currently injected  Recently inhaled measles vaccine given by nebulizer.  As far back as the 1960, influenza experts tested aerosol flu vaccines.
  • 53. RECENT TECHNOLOGIES OF PULMONARY DRUG DELIVERY:  Nebulizer:  In jet nebulizers, an aerosol is prepared by a high velocity air stream from a pressurized source directed against a thin layer of liquid solution. Ultrasonic nebulizers include the vibration of a piezoelectric crystal aerosolizing the solution.  The nebulizer can transport more drugs to the lungs than MDI or DPI.  The most common disadvantage of nebulizer are lack of possibility, higher costs of drug delivery as a result of the larger need for assistance from healthcare professionals.
  • 54. METERED DOSE INHALER (MDI):
  • 55. CONTINUED  These are the most common device for administration of aerosolized drugs.  In this technique, a medication is mixed in a canister with a propellant, and the preformed mixture is expelled in exact measured amounts upon actuation of the device.  EX: Drugs which are administered through this device
  • 56. REFERENCE 1. CONTROLLED DRUG DELIVERY CONCEPTS AND ADVANCES BY-S.P.VYAS & R.P.KHAR 2. MODERNPHARMACEUTICS FOUTH EDITION BY- BANKER & RHODES 3. ADVANCE IN CONTROLLED AND NOVEL DRUG DELIVERY BY-N.K. JAIN 4. WWW.Google.com
  • 57. ThAnK u

Related Documents